Septerna, Inc. (SEPN): Total Liabilities
$214.26M
As of 2025-12-31
$180.02M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $214.26M | +486.9% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $36.51M | +82.3% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $20.03M | n/a | 2025-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
Compare SEPN, PTGX, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗